





**FIG. 1**



3 / 16




FIG. 3




FIG. 4A-C




FIG. 5





FIG. 6



8 / 16

# Depletion of Endogenous B Cells by IV-CD19-CAR Treatment




FIG. 7E

9 / 16




FIG. 8

**10 / 16**

CD and TK allow drug susceptibility increases by up to three orders of magnitude






**FIG. 9**

miRNA de-targeting  
miR-223 specific GFP degradation in monocytes in an endogeneous model

A. Pictorial Concept  
Tool GFP Vector



Tool De-Targeting GFP Vector



B. Quantitation of GFP  
Expression in U937 monocytic  
cells, by FACS analyses.




FIG. 10A-B

|     |               |                      |                  |                            |     |
|-----|---------------|----------------------|------------------|----------------------------|-----|
| LTR | anti-BCMA CAR | Kill Switch-CD or TK | miR de-targeting | Optional immune modulators | LTR |
|-----|---------------|----------------------|------------------|----------------------------|-----|

FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15A




FIG. 15B




FIG. 16




FIG. 17




FIG 18A-D




FIG. 19A-D

15 / 16




FIG. 20A-D




FIG. 21




FIG. 22




**FIG. 23**